IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Pseudo Biologist who wrote (504)	3/20/1997 7:04:00 PM
From: Brad C. Dunlap	of 1762

Hi Max, and thanks for your insight. C2B8 is most definantly chimeric and does not infringe on PDL humanized patent. However, if I remember correctly, Idec/Genentech had a recent agreement with Xoma in which they paid them a small up front payment and a future undisclosed royalty in C2B8 revenues for the right to use Xoma's protective technology concerning their antibodies. It was disclosed by Xoma in a telephone conversation that the royalties were 2% of future revenue in C2B8. As discussed earlier CE9.1 is primatized as are the majority of the drugs that are in pre-industry clinicals. Does anyone know what specific product that is in Idec's pipeline that would be using humanized antibodies?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next